Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | PPIA | P62937 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17554783 | 0.83 | MAOB (0.50) | MAOBMRGPRX4PTGER1PPIAKDM4E | |
| SCHEMBL1330628 | 0.83 | MAOB (0.62) | MAOBMRGPRX4XDH | |
| SCHEMBL6554874 | 0.82 | MAOB (0.55) | MAOBMRGPRX4PTGER1PTGDR2PPIA | |
| SCHEMBL7129137 | 0.81 | MAOB (0.58) | MAOBMRGPRX4PTGER1GABRG2GABRB3 | |
| SCHEMBL1980141 | 0.81 | MAOB (0.58) | MAOBMRGPRX4PTGER1GABRG2GABRB3 | |
| SCHEMBL1060980 | 0.81 | MAOB (0.58) | MAOBMRGPRX4PTGER1GABRG2GABRB3 | |
| SCHEMBL1647357 | 0.81 | FOLH1 (0.62) | MAOBMRGPRX4PTGER1PTGDR2PPIA | |
| SCHEMBL31562297 | 0.80 | MAOB (0.50) | MAOBMRGPRX4PTGER1PPIAXDH | |
| SCHEMBL3490042 | 0.80 | MAOB (0.57) | MAOBMRGPRX4LMNACYP1A2KDM4E | |
| SCHEMBL6766128 | 0.80 | MAOB (0.57) | MAOBMRGPRX4LMNACYP1A2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| US-11377451-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| US-8227506-B2 | Benzamidine compound | AJINOMOTO., INC. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-8088768-B2 | Protein kinase and phosphatase inhibitors | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088768-B2 | Protein kinase and phosphatase inhibitors | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088768-B2 | Protein kinase and phosphatase inhibitors | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2012-01-03 | — | — | US | disclosed |
| EP-1698635-B1 | BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-12-14 | — | — | EP | disclosed |
| EP-1813623-B1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | NAKAMOTO KAZUTAKA | 2011-08-11 | — | — | US | disclosed |
| EP-0888271-A1 | BENZAMIDINE DERIVATIVES SUBSTITUTED BY AMINO ACID AND HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5846972-A | Bicyclic pyrimidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| US-5846970-A | Bicyclic pyrimidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| US-5753635-A | Purine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1998-05-19 | — | — | US | disclosed |
| WO-1998015547-A1 | THIO ACID DERIVED MONOCYCLIC N-HETEROCYCLICS AS ANTICOAGULANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-04-16 | — | — | WO | disclosed |
| WO-1998011094-A1 | BENZAMIDINE DERIVATIVES SUBSTITUTED BY CYCLIC AMINO ACID OR CYCL IC HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998007723-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-02-26 | — | — | WO | disclosed |
| WO-1998007725-A1 | PURINE DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-02-26 | — | — | WO | disclosed |
| US-5693641-A | ENZYME INHIBITOR TREATING BLOOD DISORDER | BERLEX LABORATORIES INC. (US) | 1997-12-02 | — | — | US | disclosed |
| WO-1997029067-A1 | BENZAMIDINE DERIVATIVES SUBSTITUTED BY AMINO ACID AND HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (DE) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | ERG28, CYP51A1, XPO1 | MAOB 1175/4885MRGPRX4 240/4885PTGER1 3057/4885 |
| US-11377451-B2 | Compositions and methods for treating cancer | TP53, EGFR, SLC2A1 | MAOB 2480/4885MRGPRX4 4699/4885PTGER1 4487/4885 |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | MAOB 1955/4885MRGPRX4 4656/4885PTGER1 4490/4885 |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | MAOB 2047/4885MRGPRX4 4685/4885PTGER1 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.